Loading...
BioCryst's Press Release
June 6, 2022

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

BioCryst's Press Release
Takeda's press release
April 28, 2022

Héma-Québec Awards Takeda Canada Two-Year Tender for HAE treatment TAKHZYRO®. Click here for the press release in French.

Takeda's press release
CSL Behring's Press Release
April 6, 2021

CSL Behring announces that HAEGARDA® is now available in all of Canada for the routine prevention of HAE attacks in adolescent and adult patients.

CSL Behring's Press Release
Takeda's Press Release
November 5, 2020

Takeda Canada announces that negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) are complete and HAE patients in Canada are now one step closer to having access to TAKHZYRO (lanadelumab injection).

Takeda's Press Release
click here for details
November 22, 2019

TAKHZYRO (lanadelumab) receives positive recommendation fro CADTH’s Canadian Drug Expert Committee (CDEC) for the routine prevention of HAE attacks.

click here for details
click here for details
September 20, 2018

Health Canada has authorized TAKHZYRO (lanadelumab), a first-of-its kind monoclonal antibody treatment for the prevention of HAE attacks.

click here for details
click here for details
August 9, 2017

Berinert approved by Health Canada for the treatment of HAE in paediatric patients.

click here for details